Neogenomics (NEO) Net Cash Flow Growth (1y) (2011 - 2026)
Neogenomics (NEO) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 498.33% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | -260.86% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 73.93% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 722.22% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | -115.29% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -58.16% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 73.12% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | -441.96% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 84.25% |
| 10 | Neogenomics | 2.05 Bn | 1.90 Bn | 91.88 Mn | 99.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.68% |
| Mar 31, 2026 | 35.27% |
| Dec 31, 2025 | -190.26% |
| Sep 30, 2025 | 35.69% |
| Jun 30, 2025 | -926.11% |
| Mar 31, 2025 | -96.88% |
| Dec 31, 2024 | -86.15% |
| Sep 30, 2024 | -59.76% |
| Jun 30, 2024 | 72.08% |
| Mar 31, 2024 | -185.08% |
| Dec 31, 2023 | 1,330.45% |
| Sep 30, 2023 | 198.02% |
| Jun 30, 2023 | 160.49% |
| Mar 31, 2023 | 213.70% |
| Dec 31, 2022 | 89.05% |
| Sep 30, 2022 | 39.98% |
| Jun 30, 2022 | 91.10% |
| Mar 31, 2022 | -102.93% |
| Dec 31, 2021 | -84.19% |
| Sep 30, 2021 | 55.85% |